Peptris Raises Rs 70 Crore Series A To Advance AI Led Drug Discovery Platform

Addressing The Structural Challenges In Drug Discovery

Drug discovery remains one of the most complex and capital intensive processes in healthcare. Despite advances in scientific research, early stage programs often fail due to time constraints, funding pressures and scientific uncertainty.

The pre clinical phase is particularly challenging. Promising molecules can be derailed before they ever reach human trials. Peptris aims to tackle this structural bottleneck by improving candidate selection and optimization at the earliest stages of research.

How Peptris Uses AI To Design Novel Molecules

Founded in 2019 by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni and Amit Mahajan, Peptris has developed artificial intelligence models designed to generate novel molecules and predict critical parameters required in drug development.

By combining computational modeling with biological and chemical insights, the platform seeks to reduce early stage failure risks and enable faster, more informed decision making.

According to the company, its approach has already resulted in the discovery of Novel Chemical Entities along with drug repurposing and rescue opportunities. Several of these programs are now progressing toward clinical development.

What Comes Next For Peptris

With fresh funding in place, Peptris plans to initiate multiple new Novel Chemical Entity programs. The company is also exploring drug repurposing and rescue initiatives involving shelved clinical stage assets from pharmaceutical companies.

As global pharma continues to look for faster and more efficient discovery models, platforms like Peptris could play a critical role in reshaping how new therapies are developed.